Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaohe Su
Observed name:
S. Xiaohe
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Zhongshan Hospital
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Zhongshan Hospital
ORCID:
0009-0006-4951-2236
Observed ORCID:
0009-0006-4951-2236
OpenAlex ID:
A5065184764
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer
2022
·
Kaifeng Jin
, Yanze Yu
, et al.
·
British Journal of Cancer
·
44
TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
2022
·
Zhaopei Liu
, Han Zeng
, et al.
·
British Journal of Cancer
·
19
TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1 / PD‐L1 blockade response in urothelial carcinoma
2024
·
Kaifeng Jin
, Jingtong Xu
, et al.
·
The Journal of Pathology
·
16
Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer
2024
·
Bingyu Li
, Kaifeng Jin
, et al.
·
Cancer Immunology Immunotherapy
·
12
PDF
POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
2024
·
Ge Liu
, Kaifeng Jin
, et al.
·
Cancer Medicine
·
9
PDF
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
2024
·
Xiaohe Su
, Kaifeng Jin
, et al.
·
British Journal of Cancer
·
9
PDF
Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer
2022
·
Yanze Yu
, Han Zeng
, et al.
·
Cancer Immunology Immunotherapy
·
9
Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression
2025
·
Kaifeng Jin
, Yawei Ding
, et al.
·
Journal for ImmunoTherapy of Cancer
·
7
PDF
Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene KDM6A mutation
2023
·
Zhaopei Liu
, Kaifeng Jin
, et al.
·
BMJ Oncology
·
5
Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study
2025
·
Zhaopei Liu
, Kaifeng Jin
, et al.
·
BMC Cancer
·
4
PDF
TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma
2025
·
Kaifeng Jin
, Jingtong Xu
, et al.
·
BMJ Oncology
·
4
PDF
Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer
2024
·
Ge Liu
, Kaifeng Jin
, et al.
·
Cancer Science
·
3
Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma
2026
·
Yawei Ding
, Kaifeng Jin
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
Natural killer cell infiltration elicits gender‐dependent dichotomous clinical outcomes in urothelial carcinoma
2025
·
Lingkai Zhang
, Zhaopei Liu
, et al.
·
Cancer
·
2
ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
·
Clinical Cancer Research
·
2
PDF
RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer
2024
·
Bingyu Li
, Kaifeng Jin
, et al.
·
Journal of Immunotherapy
·
2
Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma
2026
·
Jiaxing Sun
, Kaifeng Jin
, et al.
·
Cancer
·
1
TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma
2026
·
Xiaohe Su
, Kaifeng Jin
, et al.
·
British Journal of Cancer
Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression
2026
·
Lingkai Zhang
, Zhaopei Liu
, et al.
·
British Journal of Cancer
Data from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
Supplementary Figure S3 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Supplementary Figure S4 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Supplementary Figure S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Supplementary Table S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
Supplementary Figure S2 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma
2025
·
Zhaopei Liu
, Lingkai Zhang
, et al.
PDF
Show more works
View as search
Works count:
27
Citation count:
150
H-index:
7
I10-index:
4
Year
Topic
Type